UPDATED-AbbVie is shutting down its troubled Rova-T R&D program Shares of AbbVie Inc. rose 1.5% in premarket trade Thursday after the company announced it had shut down its troubled Rova-T research and development program. The drugmaker said it was discontinuing a late-stage trial of ...